Aseptic Process Simulation (Media Fill): Designing, Running and Defending the APS under Annex 1 and FDA

One test, different regimes: the media fill designed, run and defended with the text next to every criterion.

In the EU a single contaminated unit fails the APS, and Annex 1 §9.46 lists seven actions; the 2004 FDA guidance reasons in bands of run size; PIC/S PI 007-6 of 2011 is still published and conflicts with §9.46; ATMPs follow Part IV. This guide takes Aseptic Process Simulation from worst case to failure investigation, regime by regime: 24 chapters in six parts, 6 appendices with the full text of Annex 1 §9.32-9.49 and FDA Section IX.A, 237 pages in the English edition, 254 in the Italian one, and 17 editable tools, for €129.

Two separate editions: you choose the language. The guide and the toolkit exist as an English edition and as an Italian edition, with identical structure. Choose the ENG - English or the ITA - Italiano variant: the purchase gives access to the edition you choose, with its 17 tools in the same language.

The first edition has been rewritten from scratch. The first edition (January 2026) was published as “Guida Pratica all'Aseptic Process Simulation (Media Fill) conforme ad Annex 1 EU GMP 2022”. The second edition is a new book: every criterion has been re-read against the official text, and the scope now covers FDA, PIC/S, WHO, Part IV for ATMPs and sterile APIs. If you bought the first edition, you receive the second at no extra cost.

One turbid ampoule among 14,888 incubated units. Under Annex 1 the APS has failed, the line stops and the batches made after the run go into quarantine; under the FDA guidance, above 10,000 units, a single unit leads to an investigation. If the protocol does not state in advance which rule applies to that site, the outcome ends up choosing the rule.

The same goes for the numbers that circulate as “requirements”: incubation temperatures and durations come from FDA and from PI 007-6, because Annex 1 §9.44 asks for justified and validated conditions without setting their values; the reduced frequency for isolators is an FDA Q&A, not a European rule; the rules for ATMPs sit in Part IV, not in Annex 1.

This guide places every criterion next to the document, paragraph, status and jurisdiction it comes from, and shows how to build a single programme on the strictest criterion when the same product goes to several markets.

This edition is written on the official sources as read on 26 September 2026, including version PE 009-18 of the PIC/S GMP Guide, in force since 24/09/2026. Every document cited carries a status label; the register lists 52 sources with URL and access date, and the 100 decisions the guide leaves to the manufacturer are tracked with who decides, on what basis and where it is recorded.

The price is €129.00. Second edition, September 2026, version 2.0: 237 pages in the English edition, 254 in the Italian one, 24 chapters, 6 appendices and 17 editable tools. If you bought the first edition, you receive the second at no extra cost.

Part I — The framework (Chapters 1–4). How to read the book, with the nine labels and five reading paths by role; the 2004-2027 calendar and the status of the texts; legal force and the jurisdiction rule, from the EU to PIC/S, WHO, the US and other jurisdictions; what an APS demonstrates and what it does not, with §9.32, §9.35 and the relationship with the CCS.

Part II — Designing (Chapters 5–10). The APS within the CCS: risk assessment and worst case; inherent and corrective interventions, their frequency and representativeness; frequency, initial runs, run duration and run size; media, growth promotion, anaerobes and controls; formats and technologies — liquids, lyophilised products, powders, BFS, isolators and RABS, manual processing; closed and single-use systems, ATMPs and sterile APIs.

Part III — Running (Chapters 11–14). Protocol, roles, personnel and operator participation; batch record, interventions and unit reconciliation; environmental monitoring during the APS, with the Table 5 and Table 6 limits; incubation and inspection of units.

Part IV — Outcome (Chapters 15–17). The acceptance criteria of the EU, FDA, PIC/S, WHO and Part IV; failure: the seven §9.46 actions, investigation, batch impact, repeat runs and notifications; report, documentation and data integrity.

Part V — Governance (Chapters 18–21). The APS in the quality system: annual programme, change control and repeat of the initial validation (§9.49); operator qualification, disqualification and requalification; a single programme for several jurisdictions; the texts on the move and how to monitor them.

Part VI — Readiness and verification (Chapters 22–24). Recurring errors in seven families, each measured against an official text; the gap assessment of the APS programme across fifteen areas; four case studies in the format problem → risk → decision → activities → documentation → evidence → outcome, and 33 questions an inspector may ask.

Plus 6 appendices. The register of 52 sources with URL and access date; the status matrix by jurisdiction; the 100 decisions, each with who decides, on what basis and where it is recorded; the 17 tool sheets; the glossary; and Appendix F, with the full text of Annex 1 §9.32-9.49 and of Section IX.A of the FDA guidance, the clause-by-clause comparison and the table of divergences across five regimes.

Read the extract before you buy

The free extract is made of real pages from the book, not a sales summary: 16 pages in the English edition, 16 in the Italian one. It contains the regulatory status box with the labels and the structure of the book, the full table of contents with the real page numbers, from Chapter 15 the comparison between the Annex 1 criterion (a single unit) and the bands recommended by FDA, Case 1 of Chapter 24 in full — a failed APS with one contaminated unit, from the final reading to the restart of the line — and the overview of the 17 tools.

Who it is for. QA and QPs, sterility assurance and validation, aseptic manufacturing, QC microbiology, regulatory intelligence, consultants. It is written for whoever designs an APS programme, signs a media fill protocol or report, or runs the investigation into a failed APS, or has to defend all of this in front of an inspector, and needs to know which paragraph each criterion comes from, in which version and where it applies.

Who it is not for. It is not the guide on the line and its barriers, nor the one on environmental monitoring or the CCS: on those subjects the book states the boundary and refers to the sister guides. It does not cover sterility testing or preparation in hospital pharmacies. It does not replace the official texts and is not legal advice.

Describe your situation →